Kurse werden geladen...
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Nine Month Period Ended April 30, 2025
(Toronto, Ontario) – Helix BioPharma Corp. - TheNewswire - (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announces the filing of the Company's unaudited interim financial statements as of and for the nine month period ended April 30, 2025 (the “Financial Statements” ), the management's discussion and analysis ( “MD&A” ), and the certifications of the Chief Executive Officer and Chief Financial Officer (respectively, “CEO” and “CFO” ) relating to the Financial Statements (collectively, the “Interim Filings” ). The Interim Filings are available on the Company's profile at www.sedarplus.ca . About Helix BioPharma» Mehr auf thenewswire.com
Helix BioPharma Corp. Announces CFO Appointment to Support Strategic Growth and Upcoming Milestones
2 June 2025 – TheNewswire - (Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced that the Company has appointed Rohit Babbar, CPA as Chief Financial Officer ( “CFO” ) of the Company, replacing James B. Murphy, CPA as Fractional CFO. Rohit Babbar is Certified Public Accountant with fourteen years of experience leading accounting operations and financial strategy across fast-growing private and publicly listed small to mid-sized companies in Canada and the US. He is a Director at Brio Financial Group ( “Brio” ), a financial consulting firm that provides outsourced CFO services, financial planning and analysis, and strategic advisory support to emerging growth companies. Over the course of his career, Mr. Babbar has delivered impact across strategic growth and operational efficiency, leading transformative initiatives such as a USD 50 million private equity deal that helped drive a tenfold revenue increase from USD 20 million to USD 200 million. Mr. Babar will be supported by an experienced team of professionals from Brio specializing in accounting and finance, capital raising and administrative operations, as Helix enters a new phase of growth that includes plans to relocate to the US, pursue a NASDAQ listing, and close a substantial equity financing to support upcoming clinical studies.» Mehr auf thenewswire.com
Helix BioPharma (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") Secures Pre-IND Candidates LEUMUNA(TM) and GEMCEDA(TM) in Strategic Acquisition from the Laevoroc Group
May 20 , 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, is pleased to announce that the Company has closed the acquisitions of the assets of Laevoroc Immunology AG (“ Laevoroc Immunology ”) and Laevoroc Chemotherapy AG (“ Laevoroc Chemotherapy ”), pursuant to the asset purchase agreements dated November 28, 2024, and November 30, 2024, respectively, as amended (the “ Agreements ”). Acquisition of LEUMUNA™ and GEMCEDA» Mehr auf thenewswire.com
Unternehmenszahlen
(EUR) | Jan. 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −912,58k | 46,86% |
EBITDA | −909,27k | 50,50% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 41,51 Mio€ |
Anzahl Aktien | 74,16 Mio |
52 Wochen-Hoch/Tief | 0,78€ - 0,12€ |
Dividenden | Nein |
Beta | -0,73 |
KGV (PE Ratio) | −0,95 |
KGWV (PEG Ratio) | 0,02 |
KBV (PB Ratio) | −490,11 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Helix BioPharma Corp. ist als Immun-Onkologie-Unternehmen in Kanada tätig. Es entwickelt L-DOS47 für die Behandlung von nicht-kleinzelligem Lungenkrebs und V-DOS47, das auf den vaskulären epithelialen Wachstumsfaktor-Rezeptor 2 abzielt. Helix BioPharma Corp. hat Kooperationsvereinbarungen mit dem Moffitt Cancer Center geschlossen, um die Pharmakodynamik von L-DOS47 zu untersuchen und die Vorteile einer Kombination von L-DOS47 mit Immun-Checkpoint-Inhibitoren zu ermitteln, und mit ProMab Biotechnologies, Inc. zur Entwicklung einer neuartigen Antikörper- und chimären Antigenrezeptor-T-Zell-Therapie zur Behandlung des Multiplen Myeloms sowie Lizenzvereinbarungen mit Xisle Pharma Ventures Trust und National Research of Council Canada. Der Hauptsitz des Unternehmens befindet sich in Richmond Hill, Kanada.
Name | Helix BioPharma Co. |
CEO | Jacek Antas |
Sitz | Toronto, on Kanada |
Website | |
Börsengang | |
Mitarbeiter | 7 |
Ticker Symbole
Börse | Symbol |
---|---|
Toronto Stock Exchange | HBP.TO |
Pnk | HBPCF |
Frankfurt | HBP.F |
Assets entdecken
Shareholder von Helix BioPharma Co. investieren auch in folgende Assets